Share Name | Share Symbol | Market | Type |
---|---|---|---|
Protalix BioTherapeutics Inc | AMEX:PLX | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.05 | 2.89% | 1.78 | 1.79 | 1.72 | 1.74 | 127,659 | 22:00:00 |
Protalix BioTherapeutics, Inc.
|
(Name of Issuer)
|
Common Stock, $0.001 par value
|
(Title of Class of Securities)
|
74365A309
|
(CUSIP Number)
|
September 30, 2024
|
(Date of Event Which Requires Filing of this Statement)
|
1
|
NAMES OF REPORTING PERSONS
|
|
|
||
Whitebox Advisors LLC
|
|
|
|||
|
|
||||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
||||
(a)☐
|
|||||
(b)☒
|
|
|
|||
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|||
|
|
||||
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
Delaware
|
|
|
|||
|
|
||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
5
|
SOLE VOTING POWER
|
|
|
|
0
|
|
|
|||
|
|
||||
6
|
SHARED VOTING POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
7
|
SOLE DISPOSITIVE POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
8
|
SHARED DISPOSITIVE POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
0
|
|
|
|||
|
|
||||
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
||
☐
|
|
|
|||
|
|
||||
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
||
0.00%
|
|
|
|||
|
|
||||
12
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
||
IA
|
|
|
|||
|
|
1
|
NAMES OF REPORTING PERSONS
|
|
|
||
Whitebox General Partner LLC
|
|
|
|||
|
|
||||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
||||
(a)☐
|
|||||
(b)☒
|
|
|
|||
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|||
|
|
||||
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
Delaware
|
|
|
|||
|
|
||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
5
|
SOLE VOTING POWER
|
|
|
|
0
|
|
|
|||
|
|
||||
6
|
SHARED VOTING POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
7
|
SOLE DISPOSITIVE POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
8
|
SHARED DISPOSITIVE POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
0
|
|
|
|||
|
|
||||
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
||
☐
|
|
|
|||
|
|
||||
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
||
0.00%
|
|
|
|||
|
|
||||
12
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
||
OO
|
|
|
|||
|
|
Item 1.
|
(a).
|
Name of Issuer:
|
||
Protalix BioTherapeutics, Inc. (the “Issuer”)
|
||||
(b).
|
Address of issuer’s principal executive offices:
|
|||
2 University Plaza, Suite 100, Hackensack, NJ 07601
|
||||
Item 2.
|
(a).
|
Name of person filing:
|
||
This statement is filed by:
|
||||
(i)
|
Whitebox Advisors LLC, a Delaware limited liability company (“WA”); and
|
|||
(ii)
|
Whitebox General Partner LLC, a Delaware limited liability company (“WGP”).
|
|||
(b).
|
Address or principal business office or, if none, residence:
|
|||
The address of the business office of WA and WGP is:
3033 Excelsior Boulevard
Suite 500
Minneapolis, MN 55416
|
||||
(c).
|
Citizenship:
|
|||
WA and WGP are organized under the laws of the State of Delaware.
|
||||
(d).
|
Title of class of securities:
|
|||
Common stock, $0.001 par value (“Common Stock”)
|
||||
(e).
|
CUSIP No.:
|
|||
74365A309
|
||||
Item 3.
|
If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
|
|||
(a)
|
☐
|
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
|
||
(b)
|
☐
|
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
|
||
(c)
|
☐
|
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
|
||
(d)
|
☐
|
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
|
||
(e)
|
☐
|
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
|
||
(f)
|
☐
|
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
|
||
(g)
|
☐
|
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
|
||
(h)
|
☐
|
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
|
||
(i)
|
☐
|
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
||
(j)
|
☐
|
A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
|
||
(k)
|
☐
|
Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:
|
Item 4.
|
Ownership.
|
||||
(a)
|
Amount beneficially owned:
|
||||
As of September 30, 2024, each of WA and WGP is deemed to be the beneficial owner of 0 shares of Common Stock.
|
|||||
(b)
|
Percent of class:
|
||||
As of September 30, 2024, each of WA and WGP is deemed to beneficially own 0.00% of the Common Stock.
|
|||||
(c)
|
Number of shares as to which the person has:
|
||||
(i)
|
Sole power to vote or to direct the vote
|
0
|
|||
(ii)
|
Shared power to vote or to direct the vote
|
0
|
|||
(iii)
|
Sole power to dispose or to direct the disposition of
|
0
|
|||
(iv)
|
Shared power to dispose or to direct the disposition of
|
0
|
|||
Item 5.
|
Ownership of Five Percent or Less of a Class.
|
||||
If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the
following ☒
|
|||||
Item 6.
|
Ownership of More Than Five Percent on Behalf of Another Person.
|
||||
Not Applicable
|
|||||
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
|
||||
Not Applicable
|
|||||
Item 8.
|
Identification and Classification of Members of the Group.
|
||||
Not Applicable
|
|||||
Item 9.
|
Notice of Dissolution of Group.
|
||||
Not Applicable
|
|||||
Item 10.
|
Certification.
|
||||
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the
control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §
240.14a-11.
|
October 25, 2024
|
|
(Date)
|
|
WHITEBOX ADVISORS LLC
|
|
/s/ Gina Scianni
|
|
(Signature)
|
|
Gina Scianni
Associate General Counsel & Deputy Chief Compliance Officer
|
|
(Name/Title)
|
|
October 25, 2024
|
|
(Date)
|
|
WHITEBOX GENERAL PARTNER LLC
|
|
/s/ Gina Scianni
|
|
(Signature)
|
|
Gina Scianni
Authorized Signatory
|
|
(Name/Title)
|
October 25, 2024
|
|
(Date)
|
|
WHITEBOX ADVISORS LLC
|
|
/s/ Gina Scianni
|
|
(Signature)
|
|
Gina Scianni
Associate General Counsel & Deputy Chief Compliance Officer
|
|
(Name/Title)
|
|
October 25, 2024
|
|
(Date)
|
|
WHITEBOX GENERAL PARTNER LLC
|
|
/s/ Gina Scianni
|
|
(Signature)
|
|
Gina Scianni
Authorized Signatory
|
|
(Name/Title)
|
1 Year Protalix BioTherapeutics Chart |
1 Month Protalix BioTherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions